Navigation Links
Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Date:12/3/2007

Selected Therapy Can Advance to Phase III Clinical Trial

PALO ALTO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, today announced positive Phase II data for a combination trial involving AL-08, the Company's second generation proprietary drug candidate for the treatment of ALS. The purpose of the trial was to determine which of two compounds used in combination with AL-08 would yield the most favorable results, so that the Company could proceed to a Phase III trial. Results were presented by Paul H. Gordon, MD of Columbia University in a presentation titled "Combination Drug Selection Trial in Amyotrophic Lateral Sclerosis" at the 18th International Symposium on ALS/MND in Toronto, Canada on December 3, 2007. This study was funded by the ALS Association, Ride for Life, and the Russ Bowen and Spina Family Foundations.

The Phase II trial evaluated the neuroprotective capacity of two combinations, AL-08 and minocycline versus AL-08 with celecoxib, using group sequential design and a natural history control group for a futility analysis. The primary objective of the trial was selection of a treatment based on which drug combination appeared to slow deterioration in the ALS- Functional Score. Results showed that patients taking the AL-08/celecoxib combination showed a smaller mean decline in ALS- Functional Score compared to those taking the AL- 08/minocycline combination. Results also showed that the AL-08/celecoxib combination was non-futile compared to historical controls, and merits further evaluation. The trial was concluded ahead of schedule after the first pool of patients met the selection criteria.

"We are encouraged that the AL-08/celecoxib combination showed less of a decline in ALS-Functional Score compared to AL-08 and minocycline and historical control. Since the dif
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
2. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009).... 20 Medco Health Soluti... transformation in American healthcare through an ...delivering higher quality clinical care and fundam...medicine smarter for the benefit of patients and p... the elements in its strategy enable "Smarter Medi...
(Date:11/20/2009)... Nov. 20 Reportlinker.com announce...n its catalogue. ,, Pipettes & Pipettors -...eportlinker.com/p0164373/Pipettes--Pipettors---A-G...e&utm_medium=pr&utm_campaign=prnewswire ...egral part of any research laboratory. Large-scale...
(Date:11/20/2009)... Nov. 20 Reportlinker.com announce...n its catalogue. ,, Medical Adhesives and Seal...rtlinker.com/p0164242/Medical-Adhesives-and-Sealan...&utm_medium=pr&utm_campaign=prnewswire ,...gaining preeminence in medical devices and equipme...
Breaking Medicine Technology:Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 2Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 3Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 4Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost 5Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 2Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 3Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 4Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 5Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 6Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 7Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 8Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 9Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 10Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 11Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 12Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 2Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 3Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 4Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 5Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 6Bacterial ropes tie down shifting Southwest 10753 1Bacterial ropes tie down shifting Southwest 10753 2Guidelines Delay Start of Mammograms to Age 50 Then Every Other Year 61475 1Guidelines Delay Start of Mammograms to Age 50 Then Every Other Year 61475 2Guidelines Delay Start of Mammograms to Age 50 Then Every Other Year 61475 3Guidelines Delay Start of Mammograms to Age 50 Then Every Other Year 61475 4Survey Finds AARP Members Back Health Care Reform Legislation 61472 1Survey Finds AARP Members Back Health Care Reform Legislation 61472 2
...se is Leading Cause of Death for Infants, WESTBOR...s unit of Genzyme Corporation (Nasdaq: GENZ ), an...tory specializing in reproductive,testing to provi...ing for,spinal muscular atrophy (SMA), the most co...t will enable couples who are planning a pregnancy...
...il 14 Positive preclinical,data was presented by ... its,lead oncolytic candidate, NKTR-102 (PEG-irino...ivity in a mouse xenograft model of colorectal,can...ed at the American,Association for Cancer Research...a, the data also featured the enhanced pharmacokin...
Other Medicine Technology:Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy 2Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy 3Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy 4Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting 2Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting 3Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting 4Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting 5
(Date:11/20/2009)... , CHICAGO, Nov. 20 ... the U.S. Food and Drug Administration (FDA) to es...ening chemicals. ,, Citing concern about the s...tered without the benefit of professional consulta...said that the application of chemically based toot...
(Date:11/20/2009)... , HAIFA, Israel, November 20 /PRNewswi...rp. (CVSL.OB), http://www.CVSLMEDICAL.COM , a lea...technology, today announced that,the company,s Boa...lications,in Europe, Canada and the Far East for i...e" applicable for all angioplasty (PCTA) procedure...
(Date:11/20/2009)... , LAS VEGAS, Nov. 20 /PRNewswire-USNewswire/ -...xecutive Director of the Nevada Health Care Associ...NHCA) commends and thanks Senate Majority Leader H...a step closer toward our goal of protecting every ...home care, and preserving the strength and viabili...
(Date:11/20/2009)... editorial published online November 20 in the Jo...the exaggerated fears and hopes that often appear ... provides guidance for both the media and journals...tz, M.D., M.S., and Steven Woloshin, M.D., M.S., o...th Institute for Health Policy and Clinical Practi...
(Date:11/20/2009)...ot blood pressure readings in children with chroni... even during doctor,s office visits increasing a...g to research from Johns Hopkins Children,s Center...appears online in the Journal of American Society ...essure measurements obtained during regular doctor...
Breaking Medicine News(10 mins):Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2Health News:Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East 2Health News:Promoting healthy skepticism in the news: Helping journalists get it right 2Health News:High blood pressure easy to miss in children with kidney disease 2
... University of Medicine and Dentistry of New Jerse...Governor Jon S Corzine nominated Bruce C. Vladeck ...to become its interim president. // Vladeck w...larities. It also agreed to repay the federal gove...
... A new law has come into existence to protect the ...cal communities. Charles McManis, J.D., IP and te...ssor of Law, at Washington University in St. Louis...ities. They said that existing intellectual p...
... Agriculture has become synonymous with food produ...ng operations also provide a safe habitat for wild... warming. // "Agriculture, which includes planted ... is a huge area of land that people manage for foo...
... The outcome of bone marrow transplant could be de... protein called tumor necrosis factor (TNF). // Th...ich patients will develop graft vs. host disease (...physician to initiate appropriate preventive treat...
... MP’s have petitioned for reduction on VAT for con...ules do not warrant abolishment of VAT on condoms,...ey have strongly invoked a re-categorization of co... petition from Fins bury, a High Street retailer, ...
... We all think we know a lot about vitamins, minera...tory recent studies have created confusion regardi...be kept in mind always is that “Vitamins and other...owned neurosurgeon and GNC Corporation's national ...
Other Medicine News:Health News:TNF Protein Can Predict GVHD Bone Marrow Transplant Recipients 2Health News:Never undermine the importance of calcium and Vitamin D 2
Soft-Touch Timeter® 15 LPM Flowmeter
Oxygen Dial Flowmeters - Ohmeda
Oxygen Dial Flowmeters - Diss Handtight
...lable in oxygen, air, heliox and CO 2 . They are a...suit your application. With color coded labels and...eter is a user friendly device., ,For ISO colors ... the end of the part number., ,Please contact us ...
Medicine Products: